A powerful U.S. congressional committee has expressed significant concerns regarding unsubstantiated health claims made for various cannabis-derived products, urging the Food and Drug Administration (FDA) to increase enforcement actions. The House Appropriations Committee, in a report attached to the Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill, highlighted the “proliferation” of products making “misleading, unsubstantiated, and false claims” about addressing serious illnesses, including COVID-19 and cancer, as reported by Marijuana Moment.
Congressional Scrutiny on Medical Cannabis Product Claims
Unsubstantiated Health Claims and Safety Concerns
The committee’s report specifically cited the Federal Food, Drug, and Cosmetic Act (FFDCA), calling on the FDA to “take enforcement action against the manufacturers of any cannabis products marketed with unlawful therapeutic claims to preserve the integrity of the drug development and approval processes.” The report also noted potential contamination risks associated with such products. The committee expects the FDA to:
- Continue and increase efforts in research and data collection.
- Enhance consumer education initiatives.
- Issue guidance and policy around cannabis-based drug product development.
- Enforce against wrongdoers making unapproved medical claims.
- Preserve incentives for robust clinical study to better understand the potential therapeutic value of cannabis.
Cannabinoids in Food Products
Beyond therapeutic claims, the committee also voiced concern over the increasing presence of plant-derived cannabinoids in food products. The report states that “no cannabinoid is approved for any use in food as a food additive,” and that available data for some cannabinoids raises serious safety concerns. Since 2018, the FDA has issued over 110 warning letters to firms marketing cannabinoid products, often citing a lack of safety information. The committee encourages the FDA, in collaboration with other federal agencies and state partners, to develop a coordinated plan for appropriate enforcement actions in this area, according to Marijuana Moment.
Federal Cannabis Rescheduling Faces Legislative Hurdles
Concurrently, a separate legislative effort in the U.S. Congress aims to block the federal rescheduling of marijuana. The House Appropriations Subcommittee on Commerce, Justice, Science, and Related Agencies approved a funding bill containing a provision (Section 591) that would prevent federal officials from implementing cannabis rescheduling, as reported by Marijuana Moment and previously covered by Hemp Gazette. This move comes despite the Trump administration’s recent announcement that it is advancing federal cannabis rescheduling, with the Department of Justice (DOJ) indicating that certain state-regulated medical cannabis products and FDA-approved marijuana products would immediately move to Schedule III.
- The anti-rescheduling provision was approved on a party-line vote of 8-6 and is slated for consideration by the full Appropriations Committee.
- It remains unclear how this congressional rider, if enacted, would impact the immediate Schedule III reclassification already announced by the DOJ.
- However, its passage could potentially prevent an administrative hearing scheduled for this summer to consider broader cannabis rescheduling.
Protections for Hemp and State Medical Programs
State Medical Cannabis Program Protections
Despite the legislative push against broader rescheduling, the funding bill also includes an updated, longstanding rider (Section 531(a)) that has protected state medical cannabis programs from federal interference since 2014. This year’s provision notably includes Nebraska for the first time, addressing a previous omission despite voters in the state approving medical cannabis legalization in 2024. A new subsection, 531(b), also seeks to allow the Justice Department to enforce increased penalties for distributing cannabis within 1,000 feet of specific locations such as schools or playgrounds, a provision not enacted in prior appropriations legislation, according to Hemp Gazette‘s earlier analysis.
Industrial Hemp Research and Fiber Development
The legislative package also reinforces support for the industrial hemp sector. A longstanding rider (Section 530) protects state hemp research programs from federal interference, citing Section 7606 of the Agricultural Act of 2014. Furthermore, the committee encourages the U.S. Department of Agriculture’s (USDA) Agricultural Research Service (ARS) to conduct biotechnology and genomics research to enhance hemp cultivar development. The USDA is also urged to identify programs, such as Value-Added Producer Grants and the Business and Industry Loan Program, that can support the production and processing of plant-based fiber crops, including hemp, with a briefing requested within 180 days of the Act’s enactment, as detailed by Marijuana Moment.
These concurrent legislative and executive actions underscore the complex and evolving regulatory landscape for medical cannabis and industrial hemp in the United States, with significant implications for industry operators and policy professionals.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
